Core Insights - The SAFFRON study has completed patient enrollment, focusing on the combination therapy of savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®) for treating advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations and MET overexpression or amplification after progression on prior TAGRISSO® treatment [1][2] - This combination therapy offers a promising oral treatment option without chemotherapy for patients who have progressed after one EGFR TKI treatment, having received approval in China based on results from the SACHI study [1] Group 1 - The SAFFRON study is a global Phase III, open-label, randomized trial assessing the efficacy of the combination therapy compared to platinum-based doublet chemotherapy in patients with advanced or metastatic NSCLC [2] - The primary endpoint of the study is progression-free survival (PFS) evaluated by blinded independent central review (BICR) according to RECIST 1.1 criteria, with secondary endpoints including overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety [2] - A total of 338 patients from over 230 research centers across 29 countries have been randomized in the SAFFRON study, with top-line results expected to be announced in the first half of 2026 [2] Group 2 - If the results are favorable, the data from the SAFFRON study may support regulatory submission for the combination therapy to global regulatory authorities [2]

HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：13） 自願性公告 和黃醫藥宣佈沃瑞沙®和泰瑞沙®聯合療法用於治療泰瑞沙®治療後疾病進展的伴有 MET過表達和/或擴增的特定肺癌患者的SAFFRON全球III期研究完成患者入組 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或「HUTCHMED」）今天宣佈SAFFRON研究已完成患者入組。 SAFFRON是一項全球III期研究，旨在評估沃瑞沙® （ORPATHYS® ，賽沃替尼/ savolitinib）和泰瑞沙® （TAGRISSO® ， 奧希替尼/ osimertinib）的聯合療法用於治療既往泰瑞沙®治療後疾病進展的表皮生長因子受體（「EGFR」）突變、 伴有MET過表達和/或擴增的局部晚期或轉移性非小細胞肺癌患者 。該研究的最後一名患者已於2025年10月31日完 成入组。 該聯合 ...

Core Viewpoint - The A-share and Hong Kong stock markets experienced a pullback, particularly in the pharmaceutical sector, with innovative drugs, medical devices, and CXO concepts facing significant declines. However, several representative ETFs showed premium, indicating some capital may be moving against the trend [1][3][5]. Group 1: Market Performance - The A-share innovative drug sector saw a notable decline, with Kanghong Pharmaceutical dropping 6.79%, and other companies like ShenZhou Cell and BaiLi TianHeng falling over 5%. The only drug ETF (562050) closed down 2.22%, marking a new low in this adjustment phase [1]. - The medical sector also declined, with CXO concepts collectively falling. Notable drops included Zhaoyan New Drug at 4.81% and WuXi AppTec at 2.7%. The largest medical ETF (512170) fell 1.63% [3]. - The Hong Kong innovative drug ETF (520880) experienced a 2.61% drop after two consecutive days of gains, with a total transaction volume of 347 million yuan. Only one of the 37 covered innovative drug companies, Hengrui Medicine, saw a gain, while major stocks like Kangfang Biotech and 3SBio fell by 6% and 5.85%, respectively [5]. Group 2: Policy and Future Outlook - The recent conclusion of the five-day medical insurance negotiations and the pricing discussions for innovative drug catalogs has drawn attention, with a focus on high-value innovative drugs and CAR-T therapies. The final results of the 2025 medical insurance catalog adjustments are expected in early December [7]. - According to Open Source Securities, the current innovative drugs included in the medical insurance and commercial insurance are mostly in the early stages of volume expansion. The ongoing policy support for innovative drugs is expected to lead to rapid revenue growth for these drugs, benefiting patients and driving growth for related companies [7]. - Zhongtai Securities views the recent adjustments in the innovative drug sector as relatively benign, with no negative changes in the industry fundamentals. The pharmaceutical sector is believed to be at a relatively low point, with strong safety margins and potential for upward movement as market dynamics shift [7]. Group 3: Investment Strategies - The current market conditions are seen as a favorable time for medium to long-term investments in the biopharmaceutical sector, with recommendations for balanced allocations within the sector. This includes a rotation towards large-cap blue-chip companies and balancing investments in underperforming segments like medical devices and services [7]. - The investment strategies suggest focusing on specific ETFs: the Hong Kong innovative drug ETF (520880) for pure innovative drug exposure, the drug ETF (562050) as the only one tracking the pharmaceutical index, and the medical ETF (512170) as the largest in the market [8][9].

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently up 2.95% at HKD 24.46, with a trading volume of HKD 65.52 million, following the announcement of an upcoming investor meeting to discuss key R&D and business progress [1] Group 1: Company Developments - The company will hold an investor meeting on October 31, 2025, to share the latest advancements in innovative cancer and immune disease treatments [1] - The focus of the meeting will be on the company's new generation antibody-drug conjugate (ATTC) platform and the latest progress of its late-stage pipeline candidates [1] - The first candidate drug from the ATTC platform, HMPL-A251, is a PAM-HER2 ATTC, which combines a highly selective and potent PI3K/PIKK inhibitor as an effective payload with a humanized anti-HER2 IgG1 antibody via a cleavable linker [1] Group 2: Clinical Development - Recent preclinical data for HMPL-A251 was presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targeted Therapy and Cancer Treatment [1] - The company plans to initiate clinical development for HMPL-A251 starting at the end of 2025, with initial studies aimed at evaluating the drug's performance across multiple tumor types with varying HER2 and PAM alteration statuses [1]

Core Viewpoint - Hutchison China MediTech Limited (00013.HK) experienced a stock price increase of over 3%, currently trading at 24.46 HKD with a trading volume of 65.52 million HKD [2] Company Summary - The stock price of Hutchison China MediTech Limited rose by 2.95% as of the latest update [2] - The current trading price is reported at 24.46 HKD [2] - The total trading volume reached 65.52 million HKD [2]

Core Viewpoint - Hutchison China MediTech Limited (HCM) has seen its stock rise over 3%, currently trading at 24.46 HKD, with a trading volume of 65.52 million HKD, following the announcement of an upcoming investor meeting to discuss key R&D and business progress [1] Group 1: Company Developments - HCM will hold an investor meeting on October 31, 2025, to share the latest advancements in innovative cancer and immune disease treatments [1] - The meeting will highlight the progress of HCM's next-generation antibody-drug conjugate (ATTC) platform and the latest developments of its late-stage pipeline candidates [1] - The first candidate drug from the ATTC platform, HMPL-A251, is a PAM-HER2 ATTC, which combines a highly selective and potent PI3K/PIKK inhibitor as an effective payload with a humanized anti-HER2 IgG1 antibody via a cleavable linker [1] Group 2: Clinical Development - Recent preclinical data for HMPL-A251 was presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targeted Therapy and Cancer Treatment [1] - HCM plans to advance HMPL-A251 into clinical development starting at the end of 2025, with initial studies aimed at evaluating the drug's performance across multiple tumor types with varying HER2 and PAM alteration statuses [1]

Core Viewpoint - The Guangzhou Baiyun District has launched a three-year action plan (2026-2028) to accelerate the high-quality development of the biomanufacturing industry, aiming to achieve an output value exceeding 50 billion yuan by 2028 and establish a nationally competitive biomanufacturing industry pilot zone [1][2]. Group 1: Industry Development Plan - The action plan outlines the construction of a "11221" industrial ecosystem, which includes the establishment of one biomanufacturing innovation center, one pilot base, two achievement transformation platforms, two phases of over 1,000 acres of biomanufacturing industrial parks, and a biomanufacturing fund cluster with a scale of 10 billion yuan [2][3]. - The biomanufacturing sector is recognized as a core area for cultivating new productive forces and is a strategic competitive point for the nation [1][2]. Group 2: Current Industry Landscape - Baiyun District is a significant hub for the cosmetics industry, with over 1,200 licensed cosmetics manufacturing enterprises, accounting for about 20% of the national total, and an industry scale projected to reach 36.14 billion yuan by 2024 [2]. - The biopharmaceutical industry in the region has surpassed 31.1 billion yuan, featuring leading companies such as Guangzhou Pharmaceutical Group and Hutchison Whampoa, fostering a collaborative development advantage through "leading enterprises + research empowerment + stock upgrading" [2]. Group 3: Industrial Park and Investment - The Guangzhou Baiyun Biomanufacturing Industrial Park, as a core component of the "11221" system, is crucial for spatial layout and cluster development, with the first phase covering approximately 450 acres focused on biomedicine, cell genes, and beauty products, while the second phase will cover about 900 acres across five major industry groups [3]. - A biomanufacturing industry fund cluster with a total scale of 10 billion yuan has been established, with the first phase raising 1 billion yuan, targeting investments across the entire lifecycle of biomanufacturing enterprises from startup to Pre-IPO [3].

Core Viewpoint - Hutchison China MediTech Limited (HCM.US) shares rose over 2% pre-market, reaching $15, while its H-shares increased by 2.15% to HKD 23.76, following an investor meeting where the company shared updates on its innovative ATTC platform and product developments [1] Group 1: Company Developments - The company presented its first candidate drug HMPL-A251 from the ATTC platform, which demonstrated high selectivity and strong anti-tumor activity in various tumor cell lines during in vitro experiments [1] - Hutchison China MediTech plans to adopt a data-driven strategy to advance HMPL-A251 into clinical development starting at the end of 2025, with initial studies assessing the drug's performance across multiple tumor types with different HER2 and PAM alteration statuses [1]

致：香港交易及結算所有限公司 公司名稱: 和黃醫藥（中國）有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00013 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | 本月底法 ...

Core Viewpoint - The company is set to share its latest key research and business developments at an investor meeting on October 31, 2025, focusing on advancements in innovative cancer and immune disease treatments [1] Group 1: Research and Development Progress - The event will highlight the company's progress in its next-generation antibody-drug conjugate (ATTC) platform and the latest developments in its late-stage pipeline candidates [1] - The Chief Medical Officer emphasized the company's mission to address critical unmet medical needs in cancer and immune diseases, driving the commitment to advance innovative therapies [1] Group 2: Strategic Vision - The ATTC platform is expected to redefine precision treatment for cancer, supported by a robust product pipeline and collaborative strategies [1] - The company expresses confidence in its ability to provide transformative treatment options for patients globally in the fields of cancer and immune diseases [1]